Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
05
2019
accepted:
09
08
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
7
3
2020
Statut:
epublish
Résumé
The major stress-inducible heat shock protein 70 (Hsp70) is induced after different stress stimuli. In tumors, elevated intracellular Hsp70 levels were associated on the one hand with radio- and chemotherapy resistance and on the other hand with a favorable outcome for patients. This study was undertaken to investigate cytosolic Hsp70 (cHsp70) as a potential biomarker for progression free (PFS) and overall survival (OS) in patients with primary glioblastomas (GBM). The cHsp70 expression in tumor tissue of 60 patients diagnosed with primary GBM was analyzed by immunohistochemistry. The cHsp70 expression was correlated to the PFS and OS of the patients. A high cHsp70 expression was associated with a prolonged PFS (hazard ratio = 0.374, p = 0.001) and OS (hazard ratio = 0.416, p = 0.014) in GBM patients treated according to the standard Stupp protocol with surgery, radiotherapy and temozolomide. These data suggest that the intracellular Hsp70 expression might serve as a prognostic marker in patients with primary GBM.
Identifiants
pubmed: 31430337
doi: 10.1371/journal.pone.0221502
pii: PONE-D-19-13872
pmc: PMC6701831
doi:
Substances chimiques
Biomarkers, Tumor
0
HSP70 Heat-Shock Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221502Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neurology. 2000 Mar 28;54(6):1357-65
pubmed: 10746610
Anticancer Res. 2000 Nov-Dec;20(6B):4457-62
pubmed: 11205288
Eur J Surg Oncol. 2001 Feb;27(1):88-93
pubmed: 11237497
Cell Stress Chaperones. 2001 Oct;6(4):337-44
pubmed: 11795470
Pathol Res Pract. 2002;198(2):77-84
pubmed: 11928868
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Cancer Res. 2005 Jun 15;65(12):5238-47
pubmed: 15958569
Dis Markers. 2007;23(1-2):97-104
pubmed: 17325429
Methods. 2007 Nov;43(3):168-75
pubmed: 17920512
Methods. 2007 Nov;43(3):229-37
pubmed: 17920520
Cell Stress Chaperones. 2009 Jan;14(1):105-11
pubmed: 18663603
Lab Invest. 2008 Dec;88(12):1367-75
pubmed: 18936738
J Hepatobiliary Pancreat Sci. 2011 Jul;18(4):544-50
pubmed: 21234611
Head Neck Oncol. 2011 Feb 23;3:10
pubmed: 21345207
Cancer. 2012 Sep 1;118(17):4201-11
pubmed: 22294349
Cell Oncol (Dordr). 2012 Jun;35(3):197-205
pubmed: 22535481
J Transl Med. 2012 May 16;10:96
pubmed: 22591702
Carcinogenesis. 2013 Jun;34(6):1181-8
pubmed: 23563090
Virchows Arch. 2013 Oct;463(4):489-95
pubmed: 23913168
Cell Stress Chaperones. 2014 Jul;19(4):493-505
pubmed: 24307543
Mol Cell Biochem. 2014 Aug;393(1-2):301-7
pubmed: 24833463
Lung Cancer. 2014 Nov;86(2):262-7
pubmed: 25261232
Front Immunol. 2015 Apr 15;6:162
pubmed: 25926832
Front Immunol. 2015 Nov 02;6:556
pubmed: 26579130
Strahlenther Onkol. 2016 Mar;192(3):146-55
pubmed: 26646311
BMC Cancer. 2015 Dec 24;15:1011
pubmed: 26704632
Cancers (Basel). 2016 Jan 13;8(1):null
pubmed: 26771644
Hum Pathol. 2016 Aug;54:64-73
pubmed: 27038683
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Hematol Oncol. 2016 Sep 01;9(1):77
pubmed: 27585656
J Cell Physiol. 2018 Jan;233(1):378-386
pubmed: 28266716
Annu Rev Genet. 1988;22:631-77
pubmed: 2853609
J Neurooncol. 2017 Dec;135(3):443-452
pubmed: 28849427
Cancer Res. 1994 Jul 15;54(14):3752-7
pubmed: 8033095